Jim Weterings
Company: Bonito Biosciences
Job title: Vice President, Head of Oligonucleotide Therapeutics
Seminars:
Panel Discussion: Overcoming Design Challenges in Next-Generation Oligonucleotides to Maximize Selectivity, Potency & Clinical Impact 9:00 am
What design strategies are most effective in mitigating off-target effects? How do teams prioritize stability vs. delivery vs. potency? What are the emerging trends in oligonucleotide chemistry for next-generation therapeutics?Read more
day: Conference Day Two
Chair’s Opening Remarks 8:55 am
day: Conference Day One